# EDGAR Filing Document

**Accession Number:** 0001380106
**File Stem:** 0001380106-25-000153
**Filing Date:** 2025-6
**Character Count:** 6056
**Document Hash:** 9305000de9b01b8dedee6645a9e9c995
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001380106-25-000153.hdr.sgml**: 20250617

**ACCESSION NUMBER**: 0001380106-25-000153

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250617

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250617

**DATE AS OF CHANGE**: 20250617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RAPID MICRO BIOSYSTEMS, INC.
- **CENTRAL INDEX KEY:** 0001380106
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208121647
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40592
- **FILM NUMBER:** 251054450

**BUSINESS ADDRESS:**
- **STREET 1:** 25 HARTWELL AVENUE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 978-349-3200

**MAIL ADDRESS:**
- **STREET 1:** 25 HARTWELL AVENUE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RAPID MICRO BIOSYSTEMS INC
- **DATE OF NAME CHANGE:** 20061103

?xml version='1.0' encoding='ASCII'? rpid-20250617

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 17, 2025**

**RAPID MICRO BIOSYSTEMS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40592** | **20-8121647** |
| **(State or other jurisdiction<br>of incorporation or organization)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |
| **25 Hartwell Avenue, Lexington, MA** | | **02421** |
| **(Address of principal executive offices)** | | **(Zip Code)** |

---

**978-349-3200**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbols** | **Name of each exchange on which<br>registered** |
| Class A Common Stock, $0.01 par value per share | RPID | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 🗹

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

On June 17, 2025, Robert Spignesi, President and Chief Executive Officer of Rapid Micro Biosystems, Inc. issued a letter regarding a recently diagnosed medical condition. A copy of the letter is attached as Exhibit 99.1.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d)Exhibits.

---

| | |
|:---|:---|
| Exhibit No. | Description |
| <u>[99.1](ex991_exhibitx20250617.htm)</u> | <u>[Letter from Robert Spignesi, President and Chief Executive Officer of Rapid Micro Biosystems, Inc.](ex991_exhibitx20250617.htm)</u> |
| <u>[104](#i485106c2ea444f3ea0f57166a77879f4_1)</u> | <u>[Cover Page Interactive Data File (formatted as inline XBRL)](#i485106c2ea444f3ea0f57166a77879f4_1)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | RAPID MICRO BIOSYSTEMS, INC. | RAPID MICRO BIOSYSTEMS, INC. |
| Date: June 17, 2025 | By: | /s/ Robert Spignesi |
|  |  | Robert Spignesi |
|  |  | President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

Dear RMB Team Members and Shareholders:

I am writing on a personal note to let you know that I was recently diagnosed with a treatable form of Lymphoma. The good news is that I have an excellent care team and my doctors have given me a very good prognosis.

I have already started treatment, which is expected to last approximately four months. During this period, while my in-person time in the office and travel will be limited, I expect to continue to actively lead our business. I have informed our board of directors and the company's leadership team, and I appreciate the full support that I have received from them.

As you all know, our OneRMB culture and values enable us to accomplish great things together. I have strong confidence our team will continue to deliver exceptional results for our customers and all of our stakeholders.

I appreciate all of your support and want to thank our RMB team members for the important work they do every day. I'm very proud to be part of a company that focuses its significant talents on enabling our customers to produce lifesaving medications for patients. Now, as one of those patients, I know I'm in great hands.

Best,

Rob

<br>